gsk2256294 Report issue

Small molecule Experimental
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CNc1nc(C)nc(N[C@H]2CCC[C@@H](C(=O)NCc3ccc(C#N)cc3C(F)(F)F)C2)n1
  • InChIKey: LQHDJQIMETZMPH-ZBFHGGJFSA-N
  • Mol. Mass: 447.47
  • ALogP: 3.4
  • ChEMBL Molecule:
    gsk2256294  
More Chemistry

Pharmacology

Alternative names

gsk2256294 | n-((4-cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Brain Ischemia (Phase 1/Phase 2)

Diabetes Mellitus (Phase 2)

Endocrine System Diseases (Phase 2)

Endothelial Cells (Phase 1/Phase 2)

Glucose Metabolism Disorders (Phase 2)

Obesity (Phase 2)

Prediabetic State (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Subarachnoid Hemorrhage (Phase 1/Phase 2)

Vasospasm, Intracranial (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue